Literature DB >> 19961358

The pharmacokinetics of a long-acting OROS hydromorphone formulation.

J Turgeon1, R Gröning, G Sathyan, J Thipphawong, U Richarz.   

Abstract

IMPORTANCE OF THE FIELD: New formulations of opiods can provide round-the-clock pain relief to improve pain management and quality of life for patients with chronic pain. AREAS COVERED IN THIS REVIEW: Information and comments on the pharmacokinetic processes associated with a new once-daily formulation of the potent opiod hydromorphone. WHAT THE READER WILL GAIN: This review presents an overview of data from several small pharmacokinetic studies to gain a better perspective on the pharmacokinetic properties of a new long-acting formulation of hydromorphone. TAKE HOME MESSAGE: The development of advanced oral formulation that deliver analgesic drugs over an extended period provides new solutions to improve pain management and quality of life for patients with chronic pain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19961358     DOI: 10.1517/17425240903386658

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  5 in total

1.  A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics.

Authors:  Hye-Suk Han; Ki Hyeong Lee; Kyung Hee Lee; Jeong Seon Ryu; Young Chul Kim; Seung Woo Park; Ho-Suk Oh; Kyung Tae Park; Jung Hye Kwon; Pyung Bok Lee; Won Sik Lee; Yang Soo Kim; Joong Bae Ahn; Seong Woo Jeon; Sung Yong Lee; Young Mi Seol; Jung Hun Kang; Young Jin Yuh; So Yeon Oh; Suk Ran Kim; Jin Seok Ahn
Journal:  Support Care Cancer       Date:  2013-11-08       Impact factor: 3.603

2.  Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain.

Authors:  Joris Vandenbossche; Ute Richarz; Henry M Richards
Journal:  J Pain Res       Date:  2012-11-09       Impact factor: 3.133

3.  Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain.

Authors:  Martin E Hale; Srinivas R Nalamachu; Arif Khan; Michael Kutch
Journal:  J Pain Res       Date:  2013-05-01       Impact factor: 3.133

4.  Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study.

Authors:  Cheol Kyu Park; Hyun Wook Kang; In Jae Oh; Young Chul Kim; Yeo Kyeoung Kim; Kook Joo Na; Sung Ja Ahn; Tae Ok Kim; Young Jin Choi; Geun Am Song; Min Ki Lee
Journal:  J Korean Med Sci       Date:  2016-12       Impact factor: 2.153

5.  Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic.

Authors:  Elke Kleideiter; Chiara Piana; Shaonan Wang; Robert Nemeth; Michael Gautrois
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.